The BioMedWire Podcast

Disseminated on behalf of Quantum BioPharma, may include paid advertisements.

AUSTIN, Texas, June 2, 2026 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies.

To begin the interview, Durkacz outlined Quantum BioPharma’s primary focus on advancing its lead multiple sclerosis drug candidate, Lucid-MS.

“Quantum BioPharma is focused on a drug candidate that is trying to address an issue that exists today for people that suffer from multiple sclerosis,” he said. “If you know anybody that has the disease, you will see that over time there is a progression where they begin to lose control of parts of their body or sometimes their entire body. What our main drug candidate focus, Lucid-MS, is trying to do is reverse that damage that’s been done to people’s mobility. We believe that is something that is not addressed in any drug or therapy today in the world. There are almost three million people that suffer from this debilitating disease.”

Join IBN’s Stuart Smith for a conversation with Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPharma, as he discusses the company’s Lucid-MS development program, its unbuzzd™ commercial strategy and the milestones ahead for 2026.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 20 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine